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Summary
Objective: Dialysis-related amyloidosis (DRA) is a severe complication of maintenance hemodialysis (HD). Given the predominant deposition
of b2-microglobulin (b2m) ﬁbrils on articular cartilage in early DRA, we investigated the signiﬁcance of b2m and its relationship to distinct car-
tilage biomarkers in early DRA diagnosis in HD patients. Furthermore, we assessed the effects of b2m on articular chondrocytes in vitro.
Methods: Serum samples from 133 patients were collected before and after HD. Type II collagen cleavage product (C2C), procollagen II
c-propeptide (CPII), aggrecan chondroitin sulfate 846 epitope (CS-486) and cartilage oligomeric matrix protein (COMP) levels were deter-
mined by enzyme-linked immunosorbent assay. Primary bovine articular chondrocytes were cultured as monolayers and incubated with
b2m at 1.5 mg/l and 20 mg/l. Cartilage glucosaminoglycan synthesis was measured by [35S]sulfate incorporation. mRNA expression of inter-
leukin (IL)-1b, matrix metalloproteinases (MMPs)-3 and -9 was measured by reverse-transcriptase polymerase chain reaction (RT-PCR).
Results: Incubation with b2m at 20 mg/l signiﬁcantly decreased matrix biosynthesis. PCR analysis revealed an increase of IL-1b, as well as
MMPs-3 and -9 on the mRNA level. C2C/CPII, CS-486 and COMP levels were increased only in a subset of patients without a signiﬁcant
correlation with b2m concentrations. A subgroup analysis elucidated an increase in type II collagen degradation during the ﬁrst years of
HD, as shown by the elevation of C2C/CPII ratio.
Conclusion: b2m exerted anti-anabolic effects on articular chondrocytes in vitro and might be involved in cartilage degradation in HD patients.
b2m serum levels, however, did not reﬂect cartilage degradation in DRA. The assessment of C2C/CPII, CS-486 or COMP concentrations
apparently has minor relevance in DRA diagnosis in HD patients. However, the increased type II collagen breakdown within 5 years after
HD onset possibly mirrors the early stages of DRA. Thus, the C2C/CPII ratio could be employed in longitudinal studies, since it may reﬂect
a risk for DRA related arthropathy development in a subset of patients.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarticular complications are common amongst chronic
hemodialysis (HD) patients1 and their risk of development/
progression of arthropathies is increased, as documented
by a higher incidence of total hip arthroplasties compared
to the general population2. Today, dialysis-related amyloid-
osis (DRA) is commonly accepted as one main inducer of
arthropathies in chronic HD patients.
Besides heart failure and cerebrovascular disease, DRA
is one of the most prevalent complications disturbing quality
of life in chronic HD patients3. In fact, the vast majority of
long-term HD patients develop DRA, whereupon it’s preva-
lence increases with the duration of chronic HD
treatment4,5,3,6.*Address correspondence and reprint requests to: Klaus Bobacz,
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1336Pathophysiologically, the amyloid comprises b2-microglo-
bulin (b2m), a subunit of the major histocompatibility com-
plex class I molecule that under normal conditions is
eliminated from the circulation by the kidney. Since neither
the damaged kidney nor HD therapy efﬁciently removes
b2m from the circulation, this protein accumulates, ﬂuxes
into the synovial ﬂuid7 and tends to form b2m amyloid ﬁbrils.
Due to their afﬁnity to glucosaminoglycans and colla-
gens8e12, b2m ﬁbrils are deposited in articular structures,
preferentially in cartilaginous tissues13,14.
Clinical symptoms comprise joint swelling, joint pain and
a decrease in mobility at sites involved, such as shoulder,
hip or knee. As the disease progresses, an erosive arthrop-
athy develops displaying loss of articular cartilage, ﬁbrocar-
tilaginous replacement and subchondral bone cysts
ultimately resulting in severe skeletal morbidity15,13,16e18.
While clinical symptoms are not present until several
years after the initiation of HD5,19, b2m deposits develop
soon after renal-replacement therapy was introduced, as
evidenced by histological studies13,6. During this asymp-
tomatic stage radiological examination fails to detect
b2m-dependent alterations in affected joints6, suggesting
1337Osteoarthritis and Cartilage Vol. 16, No. 11that the early changes are only revealed by histopathologi-
cal examination. Although histology has been proposed as
the gold standard in b2m deposit assessment6 this exami-
nation cannot be easily performed in patients; thus a differ-
ent, minimal-invasive way of diagnosis would be of value
with regard to possible protective measures and risk
evaluation.
Since b2m amyloid precipitates ﬁrst on the surface of
articular cartilage13,14 and may be involved in cartilage
destruction20,13,18,14, we hypothesized that serum concen-
trations of cartilage biomarkers will be increased in
chronic HD patients. We also assumed that b2m concentra-
tions correlate with serum levels of distinct cartilage bio-
markers, rendering b2m useful as a marker of amyloid
deposition and cartilage degradation in the early stage
of DRA.
This study assessed serum concentrations of distinct car-
tilage biomarkers in 133 patients undergoing maintenance
HD. To address both, collagenous and non-collagenous
matrix components, serum levels of type II collagen cleav-
age product (C2C) and procollagen II c-propeptide (CPII),
aggrecan chondroitin sulfate 846 epitope (CS-846)21 and
cartilage oligomeric matrix protein (COMP)22,23 were mea-
sured. In case of C2C and CPII the results are presented
as the ratio of C2C/CPII, whose increase correlates with
cartilage destruction24,25. Moreover we investigated the
effects of b2m on articular chondrocyte biosynthetic activity
in vitro.Patients and methodsPATIENTSAfter obtaining approval from our hospitals’ ethics committee (EK Nr: 124/
2004), chronic HD patients of our nephrology department received a written
informed consent, which had to be returned signed prior to study initiation
and serum sample collection. Patients with a history of diagnoses of joint dis-
eases were excluded from the study. A total of 133 patients were enclosed.
While designing and performing this study we adhered to the Declaration of
Helsinki.
Patients’ age ranged from 26 years to 83 years, at a mean of 60.2 years.
The mean duration of the HD period was 3.6 years (range: 1e26 years). b2m
levels were elevated in all patients, at a mean of 23.59 mg/l and ranged from
10.39 mg/l to 44.26 mg/l. In all patients HD was performed three times per
week using high ﬂux membranes.
The patient cohort was further divided into three groups according to HD
duration: 46.6% of the patients underwent HD for 1e2 years (1e2 years HD
group), 36.8% for 3e5 years (3e5 years HD group) and 16.6% for >5 years
(>5 years HD group).
Moreover, to take the factor joint pain into account all study subjects re-
ceived a brief patient driven questionnaire; patients were asked to provide
information concerning joint pain during the past 2 years (possible answers:
yes or no) and if appropriate, to complete a visual analog scale (VAS) for
pain (range 0e10). From the originally distributed 133 questionnaires 93
were returned completed.
The serum control group consisted of 15 volunteers (hospital workers)
without any history of joint symptoms. The mean age of the control group
was 31.9 years (range: 25e43 years). To minimize the chance of including
subjects with osteoarthritic joint alterations, which might inﬂuence cartilage
markers levels, we arbitrarily deﬁned 45 years as threshold for the inclusion
of healthy control subjects, according to the epidemiological study by Oliveria
et al.26. The sample size calculation was based on previous publications in
this ﬁeld which yielded a sample size of less than 15 for aw100% difference
with regard to serum levels of C2C, CPII and CS-84627.ACQUISITION OF SERUM SAMPLES AND MARKER ASSAYSAfter the long (2 days) interval between two HD sessions (Friday to
Monday and Saturday to Tuesday, respectively), blood samples were
collected in sterile tubes without additives before and after HD was carried
out. Samples were allowed to clot at room temperature and centrifuged.
Thereafter serum was stored in aliquots at 70C.
The cartilage biomarkers C2C, CPII and CS-846 (all IBEX Tech. Inc., Mon-
treal, Quebec, Canada) as well as COMP (AnaMar Medical AB, Go¨teborg,Sweden) were quantiﬁed in the patients’ sera by enzyme-linked immunosor-
bent assays (ELISAs), according to the manufacturers’ instructions.
b2m levels were assessed routinely by microparticle enzyme
immunoassay.CELL CULTUREHooves from 18e20-month-old adult cows (n¼ 3) were obtained from a lo-
cal slaughterhouse (Steininger; Simondsfeld, Austria). Since the hooves and
the metacarpophalangeal joints are not used in meat processing and consti-
tute waste material, no ethics committee approval was required. Metacarpo-
phalangeal joints were prepared by removal of skin and appendages.
Cartilage slices were aseptically obtained from the metacarpophalangeal
joints and were washed twice in phosphate-buffered saline (PBS; GibcoBRL,
Life Technologies, Paisley, Scotland) and ﬁnely minced. Chondrocytes were
released by overnight digestion in 0.2% collagenase B (Boehringer Man-
nheim, Mannheim, Germany) at 37C in a shaking waterbath. An aliquot of
50 ml of the isolated cells was stained with 50 ml Trypanblue for viability
assessments.
Isolated cells were grown as monolayer cultures in an 1:1 mixture of
Dulbecco’s modiﬁed Eagle’s medium (DMEM 25 mM Hepesþ 4500 mg/l
glucoseþ pyridoxine, without sodium-pyruvate; Life Technologies, Gaithers-
burg, MD, USA) and Ham’s F12 (Ham’s F-12þ L-glutamine; Life Technolo-
gies, Gaithersburg, MD, USA) containing 10% (v/v) fetal calf serum (FCS;
PAA Laboratories, Linz, Austria) and antibiotics/antimycotics (100 U/ml pen-
icillin G, 100 mg/ml streptomycin, and 0.25 mg/ml amphotericin B; Life Tech-
nologies). For the analysis of sulfated glucosaminoglycan (sGAG) synthesis,
primary chondrocytes were plated in 24 multiwell-plates (Costar, Cambridge,
MA, USA) in quadruplicates at a density of 2 105 cells/well. At 90% conﬂu-
ence chondrocyte cultures were switched to a chemically deﬁned serum free
basal medium (BM)28 and stimulated with b2m (Millipore Corporation, Biller-
ica, MA, USA) at physiological and pathological concentrations29 of 1.5 mg/l
or 20 mg/l, respectively. Cultures that were stimulated with 10% FCS served
as positive controls. Over a period of 5 days b2m and medium were replaced
every second day. Cultures were maintained at 37C in humidiﬁed air and
5% CO2.
For total RNA preparation, 1 106 primary cells/well were seeded in six-
well tissue-culture plates (Costar) and cultured as described above.BIOSYNTHESIS OF sGAGs AND REVERSE-TRANSCRIPTASE
POLYMERASE CHAIN REACTION (RT-PCR) ANALYSIS[35S]sulfate incorporation into sGAGs was performed as previously de-
scribed30. Brieﬂy, cell cultures were washed twice with PBS and labeled
with 20 mCi/ml of [35S]sulfate (carrier-free, Amersham, Buckinghamshire,
UK) in a sulfate-free/serum-free medium for 3 h at 37C. Chondrocytes
were extracted in guanidine-HCl buffer (4 M guanidine-HCl, 50 mM sodium
acetate buffered at pH 7.2, in the presence of protease inhibitors). Unincor-
porated isotope was removed by using Sephadex G-25 (PD-10 columns;
Pharmacia Biotech, Piscataway, NJ, USA) gel chromatography. Values
were obtained by liquid scintillation counting (1410 liquid scintillation counter;
Wallac Oy, Turku, Finland) of aliquots from void volume fractions and nor-
malized for DNA content. DNA content was assessed by use of bisbenzimide
(Hoechst 33258; Sigma-Aldrich, St. Louis, MO, USA)31.
RT-PCR was used to determine the presence of interleukin (IL)-1b, matrix
metalloproteinases (MMPs)-3 and -9 mRNA. Total RNA was extracted using
a commercially available kit (RNeasy Kit, Quiagen, Valencia, CA, USA). For
RT-PCR 1 mg total RNA of each sample was copied into cDNA in a 20 ml re-
action using the First-Strand cDNA Synthesis Kit (Pharmacia, Uppsala, Swe-
den). One microliter aliquots were ampliﬁed in a previously described
reaction mixture30. The reaction proﬁle was used for all experiments: an ini-
tial denaturation at 94C for 1 min, followed by 30 cycles at 94C for 1 min;
52C for 1 min; and 72C for 40 min, and an additional 10 min extension step
at 72C after the last cycle. Ampliﬁcation reactions were performed in an air
thermal cycler (Idaho Technology Inc., Idaho Falls, ID, USA). The ampliﬁed
DNA fragments were visualized with a Fluorimager (Biorad Laboratories,
Hercules, CA, USA). Negative controls where cDNA was omitted from the re-
action, as well as positive controls [total RNA derived from IL-1b stimulated
peripheral blood mononuclear cells (PBMCs)] were run in parallel.
Primer sequences used are as follows: IL-1b: F50-aaaca-
gatgaagagctgcatccaa-30, R50-caaagctcatgcagaacaccactt-3032, MMP-3:
F50-gaacaatggacaaaggatacaaca-30, R50-ttcttcaaaaacagcatcaatctt-3033, MMP-9:
F50-cactgtccacccctcagagc-30, R50-gccacttgtcggcgataagg-3033 and b-actin: F50-
tgtgatggtgggaatgggtcag-30 R50-tttgatgtcacgcacgatttcc-30.STATISTICAL ANALYSISThe statistical signiﬁcance of differences in the median values among the
groups was determined by KruskaleWallis one way analysis of variance on
ranks; to isolate the groups that differ from others the multiple comparison
1338 I.-G. Sunk et al.: Cartilage markers in hemodialysisprocedure (Dunn’s method) was used. ManneWhitney rank sum test was
used to determine signiﬁcant differences between groups. To examine rela-
tionships between b2m and cartilage biomarker levels the Spearman’s rank
order correlation was used. Student’s t test was employed to assess differ-
ences between stimulated and unstimulated chondrocyte cultures. A P value
less than 0.05 was considered signiﬁcant.
Resultsb2M AFFECTS BIOSYNTHETIC ACTIVITY OF ARTICULAR
CHONDROCYTESPrimary bovine articular chondrocytes were grown as
monolayer cultures and incubated with b2m at low
(1.5 mg/l) and high (20 mg/l) concentrations. As a functional
reﬂection of chondrocytes’ biosynthetic activity [35S]sulfate
incorporation rate into newly synthesized matrix macromol-
ecules was measured. We found a 2.5 fold decrease in iso-
tope uptake in chondrocyte cultures stimulated at high
concentrations of b2m [97.1 19.2 (mean S.E.M.) counts
per minute/mg (cpm/mg) DNA], compared to unstimulated
controls (252.7 14.8 cpm/mg DNA) and this decrease
was statistically signiﬁcant (P< 0.0001). Cells cultured in
the presence of low b2m concentrations, however,
displayed no change in sGAG synthesis in comparison to
the control group (b2m 1.5 mg/l: 248.6 19.4 cpm/mg
DNA vs BM; P¼ 0.9) [Fig. 1(A)].
Monolayers that were incubated with 10% FCS served as
positive controls and showed an expected increase in
sGAG synthesis (10% FCS: 851.2 83.6 cpm/mg DNA vs
BM; P< 0.0001).
Moreover, we investigated the expression of IL-1b and
MMPs-3 and -9 as surrogate markers of cartilage catabo-
lism by RT-PCR analysis and found a remarkable upregula-
tion of all three genes in chondrocytes incubated at high
b2m concentrations, while b2m at 1.5 mg/l displayed no
such effect [Fig. 1(B)]. mRNA derived from IL-1b stimulated
PBMCs was used as positive controls.
These in vitro data suggest an anti-anabolic effect of b2m
on articular chondrocytes.SERUM LEVELS OF CARTILAGE BIOMARKERS
IN CHRONIC HD PATIENTSIn order to elucidate whether serum concentrations of ei-
ther C2C/CPII, CS-846 or COMP are elevated in patients
undergoing chronic HD, we determined the serum levels
of each marker before (prae-HD) and after (post-HD)
dialysis.
The C2C/CPII ratio values, median (range), prae-HD
[0.107 (0.007e0.4)] and post-HD [0.106 (0.02e0.87)] did
not signiﬁcantly differ from each other or that of the healthy
control group [0.081 (0.025e0.209)]; P> 0.05 [Fig. 2(A)].
Furthermore, there was no correlation between b2m levels
and C2C/CPII, as calculated by Spearman’s test
(rs¼0.11, P¼ 0.22) [Fig. 3(A)].
Serum concentrations of CS-846 prae-HD [178 (76e
841) ng/ml] and from healthy controls [179 (87e328) ng/
ml] did not vary signiﬁcantly (P¼ 0.92), whereas the CS-
846 serum levels from the post-HD measurements [127
(2e689) ng/ml] were markedly decreased compared to the
prae-HD group (P< 0.0001) as well as to healthy controls
(P< 0.01) [Fig. 2(B)], likely reﬂecting elimination of CS-
846 by dialysis. Moreover, we found a weak, but signiﬁcant
correlation between CS-846 and b2m concentrations
(rs¼ 0.18, P< 0.04) [Fig. 3(B)], however when values within
the normal ranges (in 89% of 133 patients) were excluded,
no correlation was seen.ForCOMPserum levelswe foundnodifferencebetween the
prae-HD [13.1 (2.9e33.4) U/l], post-HD [12.3 (5.2e43.3) U/l]
or the healthy control group [10.2 (6.4e20.5) U/l]; P> 0.05
[Fig.2(C)].Also,asshown inFig.3(C), therewasnocorrelation
with b2m serum levels (rs¼ 0.09, P¼ 0.29).
Additionally, we investigated the inﬂuence of patient age
and sex. The patients’ age ranged from 26 years to 83
years with an average of 60.2 years. While serum b2m
levels were negatively correlated with patient’s age
(rs¼0.24, P< 0.007), there was no correlation between
age and the levels of C2C/CPII, CS-846 or COMP. Further-
more C2C/CPII, CS-846 or COMP values measured in arbi-
trarily deﬁned age groups (0e35 years, 36e50 years and
>50 years) did not signiﬁcantly differ among each other or
from values obtained from the healthy control group (data
not shown).
Sex was almost equally distributed including 58.6% male
and 41.4% female individuals. We found no signiﬁcant differ-
ence for C2C/CPII, CS-846 or COMP between the male and
the female patients group compared to each other or to their
respective healthy control groups (data not shown).INFLUENCE OF HD PERIOD ON CARTILAGE BIOMARKER
LEVELSTo take the factor chronic HD period into account, we
evaluated its inﬂuence on cartilage biomarker
concentrations.
While investigating C2C/CPII values of chronic HD pa-
tients with regard to the individual HD periods, we found
an increased C2C/CPII ratio in the 1e2 years HD group
[0.113 (0.028e0.391); P< 0.04] and in the 3e5 years HD
group [0.12 (0.007e0.403); P< 0.02] compared to that of
healthy controls [0.081 (0.025e0.209)] [Fig. 4(A)]. In the
>5 years HD group [0.081 (0.031e0.188)], the values de-
creased to the ranges of the control group. For CS-846
and COMP there was no signiﬁcant difference between
the three groups or in comparison with healthy controls
[Fig. 4(B) and (C)].
The b2m concentrations, however, increased with the du-
ration of the HD period and were positively correlated
(rs¼ 0.37, P< 0.0001); moreover adjustment for age did
not diminish the association between HD duration and
b2m concentrations (r¼ 0.28, P< 0.002). When we divided
the study cohort into three groups (1e2 years HD, 3e5
years HD and >5 years HD), b2m levels were signiﬁcantly
elevated in the 3e5 years HD group [24.5 (16e44.3) mg/l]
compared to the 1e2 years HD group [20.6 (10.4e35.5) mg/
l; P< 0.002] and remained constant after 5 years of HD
>5 years HD group [26.6 (14.7e42.7) mg/l; P¼ 0.27]. How-
ever, b2m concentrations did not correlate with C2C/CPII
values of the 1e2 years HD, 3e5 years HD or >5 years
HD groups (data not shown).C2C/CPII, CS-846 AND COMP LEVELS IN RELATION
TO PATIENTS JOINT PAINWe were further interested whether the determination of
patients joint pain would be related to changes in cartilage
biomarkers.
The factor joint pain had no inﬂuence of the values of
C2C/CPII, CS-846 or COMP, since we found no statistical
differences between the ‘‘joint pain’’, ‘‘no joint pain’’ and
the healthy control group [Fig. 5(A)e(C)]. Moreover, b2m
levels did not differ in patients, who described joint pain
compared to those without joint pain (data not shown).
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Fig. 1. (A) Bovine articular chondrocytes were obtained from the metacarpophalangeal joints of adult cows (n¼ 3). Cells were cultured as
monolayers, incubated with b2m at 1.5 mg/l and 20 mg/l for 5 days and subsequently labeled with [35S]sulfate for 3 h. The incorporated ra-
diolabel into the newly synthesized matrix macromolecules was then measured and normalized to DNA content of the cells. Cultures incu-
bated with BM alone served as negative controls; those stimulated with 10% FCS represent positive controls. Values are given as cpm/mg
DNA. Values are the mean and S.E.M. *P< 0.0001 vs BM. (B) mRNA expression of IL-1b, metalloproteinases (MMP)-3 and -9 was evaluated
in bovine articular chondrocytes after incubation with BM (unstimulated control) and b2m at 1.5 mg/l or 20 mg/l. Equal loading of the samples
was conﬁrmed by b-actin expression. The ﬁgure is representative for three experiments.
1339Osteoarthritis and Cartilage Vol. 16, No. 11The evaluation of the VAS for pain scores provided no fur-
ther information, as no differences between the tested
groups were revealed (data not shown).Discussion
DRA is a complication of end-stage renal disease and
long-term HD, where the elimination of b2m is impaired
and b2m cumulates to form amyloid ﬁbrils. These ﬁbrils
are deposited mainly on articular structures and in the early
stage of DRA predominantly on articular cartilage13,14.
This study investigated the effect of b2m on cartilage bio-
synthetic activity in vitro. Furthermore, the signiﬁcance of
b2m and its relation to distinct cartilage biomarkers in early
DRA diagnosis were assessed. Here we report an anti-
anabolic effect of b2m on articular chondrocytes, however,
the tested cartilage biomarkers were only elevated in a sub-
set of patients without correlation with b2m. A noteworthy
increase in type II collagen breakdown early after initiation
of HD might reﬂect early changes in DRA.
According to histological examinations three stages of
b2m amyloid deposition have been determined. The earliest
stage (stage I), the cartilage-restricted stage, was charac-
terized by small b2m amyloid deposits exclusively on the
cartilage surface in the absence of inﬂammation13,14.
When the disease progressed, the amyloid layer on the car-
tilage surface became thicker, adjacent articular tissues
were involved (stage II) and macrophages appeared around
capsular or synovial deposits (stage III).
As a molecular consequence of these alterations an
increased expression in MMP synthesis in articular tissues
has been proposed that might be responsible for jointdestruction in DRA. This hypothesis was strengthened by
the immunohistochemical study of Ohashi and co-workers,
who found increased MMP expression in synovial ﬁbro-
blasts, osteoclasts and chondrocytes in histological speci-
mens obtained from DRA patients34. In vitro studies by
Migita and Moe further extended these ﬁndings by demon-
strating increased MMP expression in synovial ﬁbroblasts
upon stimulation with b2m35,36. Although these studies
shed new light on the pathogenesis of joint destruction in
DRA, they could not explain the role of chondrocytes in
this disorder. Our in vitro experiments, however, revealed
an anti-anabolic effect of b2m on primary articular chondro-
cytes, as shown by decreased sGAG synthesis, and our
ﬁndings are well in line with a previous study showing
a b2m-dependent decrease in chondrocyte proliferation37.
The observed upregulation of IL-1b, MMPs-3 and -9
mRNA upon b2m stimulation even suggests the promotion
of a catabolic state in articular cartilage.
Given the fact that in the initial stage of DRA the
precipitation of b2m deposits accumulate predominantly in
articular cartilage, our ﬁndings indicate that articular
chondrocytes might play an important role as primary
responders in DRA.
We further wanted to elucidate whether cartilage catabo-
lism is reﬂected by an increase in serum biomarker concen-
trations in vivo. MMPs would appear as likely candidates,
however, increased MMP levels in HD patients have been
described before and should be considered as markers of
chronic inﬂammation due to different causes, such as pro-
gressive renal sclerosis, atherosclerosis or the HD process
itself38,39. As MMPs seemed not to be appropriate markers
for cartilage degradation in DRA we focused on more spe-
ciﬁc molecules that provide a direct measure of cartilage
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Fig. 2. Serum levels of the cartilage biomarkers. (A) C2C/CPII, (B)
CS-846 and (C) COMP in chronic hemodialysis (HD) patients mea-
sured before (prae-HD) and after HD (post-HD). The healthy control
group comprised 15 volunteers (hospital workers) without any
history of joint symptoms. Horizontal lines represent the median
for each patients group.
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Fig. 3. Correlation between b2m and (A) C2C/CPII ratio, (B) CS-
846 and (C) COMP serum levels in 133 chronic HD patients. Rela-
tionship between the serum levels was calculated by Spearman’s
test. The gray boxes represent serum levels from healthy controls.
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breakdown products derived from collagenous (C2C and
CPII) and non-collagenous (CS-846 and COMP) matrix
components. While none of these biomarkers was elevated
in the total HD patients cohort compared to healthy controls,
a further subgroup analysis regarding the length of the HD
period was performed. In patients, who were subjected to
chronic HD for less than 5 years (1e2 years and 3e5 years
HD groups) a signiﬁcant increase in type II collagen degra-
dation was seen, as reﬂected by an elevated C2C/CPII ra-
tio. These time spans are congruent with the mean duration
after HD initiation where the ﬁrst b2m deposits are present
in DRA patients, namely 39 months for stage I and 56
months as for stage II14. Our data therefore suggest that
an increase in C2C/CPII ratio might mirror the stage of ﬁrstamyloid deposits on articular cartilage and its subsequent
degradation, at least in a subset of patients. The question
arises why no increase in CS-846 or COMP levels was de-
tectable. We hypothesize that after b2m-induced enzymatic
release the majority of those molecules, or at least the
sGAGs, were incorporated into the b2m deposits, as
sGAGs enhance b2m amyloid formation and stabilize the
ﬁbrils40. On the other hand, in the early stage of DRA the
rate of CS-846 and COMP breakdown/release might have
been low and thus beyond the limit of detection.
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Fig. 4. Temporal pattern of cartilage biomarker levels in relation to
the HD duration. The HD patient cohort was divided into three sub-
groups, 1e2 years HD (62 patients), 3e5 years HD (49 patients)
and >5 years HD (22 patients). (A) C2C/CPII ratio, (B) CS-846
and (C) COMP serum concentrations were assessed by ELISA.
Serum samples obtained from 15 volunteers without any history
of joint symptoms served as healthy controls. Horizontal lines rep-
resent the median for each patients group.
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Fig. 5. Determination of patients’ joint pain in relation to cartilage
biomarker serum levels in chronic HD patients. All study subjects
received a patient driven questionnaire; from the originally distrib-
uted 133 questionnaires 93 were returned completed. (A) C2C/
CPII, (B) CS-846 and (C) COMP serum levels were investigated
in a ‘‘joint pain’’ (47 patients) and a ‘‘no joint pain’’ (46 patients)
group. Healthy serum controls were obtained from 15 volunteers
without any history of joint symptoms. Horizontal lines represent
the median for each patients group.
1341Osteoarthritis and Cartilage Vol. 16, No. 11In our patient population we further observed a normaliza-
tion of the C2C/CPII ratio after 5 years of HD. As DRA prog-
resses, more and more amyloid is formed and deposited
and thus more matrix constituents are incorporated into
the amyloid ﬁbrils. Since b2m also shows an afﬁnity to
type II collagen10 the incorporation of this matrix component
into b2m complexes cannot be ruled out, thereby explaining
the decrease in its serum levels.
The most convenient and cost-efﬁcient way in determin-
ing cartilage degradation in DRA would be the assessmentof b2m levels, provided that b2m correlated with increased
concentrations of cartilage biomarkers, as assumed in our
original hypothesis. This hypothesis was initially supported
by our ﬁndings of increased b2m concentrations with the
duration of the HD period. However, there was no correla-
tion between b2m and the increased ratio of C2C/CPII.
Thus, these data together with the ﬁnding that serum b2m
levels did not differ among patients with or without DRA29
ﬁnally render b2m an irrelevant marker for this question.
Taken together we showed a direct effect of b2m on
articular chondrocytes in vitro, apparently inducing cartilage
1342 I.-G. Sunk et al.: Cartilage markers in hemodialysisdegradation. Serum concentrations of the cartilage markers
CS-846, COMP and C2C/CPII, however, were increased in
only a subset of patients without a signiﬁcant correlation
with b2m. Thus, we conclude that b2m levels do not reﬂect
amyloid deposition and cartilage degradation in DRA. More-
over, the measurement of cartilage markers seems to be of
minor relevance for DRA diagnosis in HD patients in daily
clinical practice. Nevertheless, assessment of the C2C/
CPII ratio could be considered in longitudinal studies, since
it may be useful for the risk evaluation of DRA related
arthropathy development in at least a subset of patients.Conﬂict of interest
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